Concepedia

Neurolixis (United States)

N(

Statistics

Publications

72

Citations

2.7K

Authors

3

Location

Park Ridge, United States

Neurolixis (United States) is a company institution in Park Ridge, United States known for neuropharmacology, neuroscience, and medicine.

HomepageWikipediaROR

Top concepts

Publications

72

Inflammatory Cytokine Patterns Associated with Neurological Diseases in Coronavirus Disease 2019

Otávio de Melo Espíndola, Yago Côrtes Pinheiro Gomes, Carlos Otávio Brandão et al. · Annals of Neurology · 2021 · 84 citations · Full text

, , +21

NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat

Hanna Iderberg, Andrew C. McCreary, Mark A. Varney et al. · Experimental Neurology · 2015 · 76 citations

, , +12

Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia

Hanna Iderberg, Andrew C. McCreary, Mark A. Varney et al. · Neuropharmacology · 2015 · 67 citations

, , +9

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study

Guillaume Becker, Radu Bolbos, Nicolas Costes et al. · Scientific Reports · 2016 · 54 citations · Full text

Activation of 5-HT1A postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia

Rafael Pazinatto Aguiar, Lígia Mendes Soares, Erika Meyer et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2019 · 54 citations · Full text

Rows per page

1–5 of 72

Authors

3

  1. MA
    Mark A. Varney

    Neurolixis (United States), United States

    96 publications · 5.7K citations

    36

    h-index

  2. SC
    Sharon C. Bossert

    Neurolixis (United States), United States

    1 publications · 43 citations

    1

    h-index

  3. CT
    Crystal Tasber

    Neurolixis (United States), United States

    1 publications · 43 citations

    1

    h-index

Rows per page

1–3 of 3